Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic imm… Read more
Kaleido Biosciences Inc (KLDO) - Net Assets
Latest net assets as of March 2022: $10.61 Million USD
Based on the latest financial reports, Kaleido Biosciences Inc (KLDO) has net assets worth $10.61 Million USD as of March 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($50.14 Million) and total liabilities ($39.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $10.61 Million |
| % of Total Assets | 21.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.97 |
Kaleido Biosciences Inc - Net Assets Trend (2016–2021)
This chart illustrates how Kaleido Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kaleido Biosciences Inc (2016–2021)
The table below shows the annual net assets of Kaleido Biosciences Inc from 2016 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $10.61 Million | -48.25% |
| 2020-12-31 | $20.50 Million | -58.07% |
| 2019-12-31 | $48.88 Million | -16.00% |
| 2018-12-31 | $58.20 Million | +233.23% |
| 2017-12-31 | $-43.68 Million | -158.21% |
| 2016-12-31 | $-16.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kaleido Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34754200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $43.00K | 0.41% |
| Other Components | $375.03 Million | 3535.69% |
| Total Equity | $10.61 Million | 100.00% |
Kaleido Biosciences Inc Competitors by Market Cap
The table below lists competitors of Kaleido Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Petrolimex Saigon
VN:PSC
|
$4.25K |
|
Supalai PCL
STU:NYVL
|
$4.25K |
|
CN MINSHENG BK -H-
MU:GHFH
|
$4.25K |
|
C W Mackie PLC
CM:CWMN0000
|
$4.25K |
|
NB Distressed Debt Investment Fund Ltd
LSE:NBDD
|
$4.24K |
|
Credit Agricole Egypt
EGX:CIEB
|
$4.24K |
|
CHANGAN MINSHENG-H-
BE:W8R
|
$4.24K |
|
HBOR3F
SA:HBOR3F
|
$4.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kaleido Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 20,496,000 to 10,607,000, a change of -9,889,000 (-48.2%).
- Net loss of 90,288,000 reduced equity.
- Share repurchases of 339 reduced equity.
- New share issuances of 69,925,000 increased equity.
- Other factors increased equity by 10,474,339.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-90.29 Million | -851.21% |
| Share Repurchases | $339.00 | -0.0% |
| Share Issuances | $69.92 Million | +659.23% |
| Other Changes | $10.47 Million | +98.75% |
| Total Change | $- | -48.25% |
Book Value vs Market Value Analysis
This analysis compares Kaleido Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.75 | $0.00 | x |
| 2017-12-31 | $-1.95 | $0.00 | x |
| 2018-12-31 | $1.98 | $0.00 | x |
| 2019-12-31 | $1.90 | $0.00 | x |
| 2020-12-31 | $0.61 | $0.00 | x |
| 2021-12-31 | $0.25 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kaleido Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -851.21%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8178.26%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 4.73x
- Recent ROE (-851.21%) is below the historical average (-253.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.99 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.19 Million |
| 2018 | -106.10% | 0.00% | 0.00x | 1.47x | $-67.56 Million |
| 2019 | -173.91% | 0.00% | 0.00x | 1.68x | $-89.90 Million |
| 2020 | -389.32% | -8184.21% | 0.02x | 2.90x | $-81.85 Million |
| 2021 | -851.21% | -8178.26% | 0.02x | 4.73x | $-91.35 Million |
Industry Comparison
This section compares Kaleido Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kaleido Biosciences Inc (KLDO) | $10.61 Million | 0.00% | 3.73x | $4.24K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |